2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting
- Study type
- Clinical guideline
- Study name
- MASCC/ESMO 2023
- Design
- Clinical guideline based on expert consensus (2022 MASCC/ESMO consensus conference)
- Sample size
- Consensus committee of 34 multidisciplinary health professionals and three patient representatives
- Source
- ESMO Open · 2024
In plain words
Nausea and vomiting are among the most distressing side effects of cancer treatment. This international guideline, written by a group of specialists and patient representatives, reviews ways to prevent and control this side effect during chemotherapy and radiotherapy. The recommendations are for the first course of treatment and may change for later courses. Be sure to discuss the right medicine plan with your treating doctor.
Study population
This guideline is intended for patients receiving antineoplastic treatment (chemotherapy and radiotherapy) who are at risk of treatment-induced nausea and vomiting. The published abstract gives no more detailed inclusion criteria.
Endpoints
This guideline covers emetogenic risk classification and the prevention and management of treatment-induced nausea and vomiting. The recommendations were based on evidence-based data (level of evidence) and the collective expert opinion of the authors (grade of recommendation).
Safety and side effects
Not applicable to this guideline, and the published abstract gives no information on adverse events.
Clinical significance and place in guidelines
This document is a joint MASCC and ESMO update and provides a framework for emetogenic risk classification and the prevention and management of treatment-induced nausea and vomiting. According to the abstract, all recommendations apply to the first course of antineoplastic treatment and may need modification in later courses. The details of the recommendations (drugs, doses and the level of evidence for each) are not in the abstract and must be taken from the full text of the guideline and verified.
Limitations
The PubMed record for this paper has no structured abstract and includes only key points; therefore, specific recommendations, doses and levels of evidence are not included in this card and must be taken from the full text of the guideline. The recommendations apply only to the first course of treatment.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.